Last Updated on January 14, 2024 by The Health Master
The United States Food & Drug Administration (USFDA) concluded a pre-approved inspection at Lupin’s biotech manufacturing facility in Pune.
Following the inspection, the regulator issued a form 483 with 17 observations.
However, the company does not expect an impact on existing revenues from this facility following the observations. The pre-approved inspection was conducted earlier this month.
Lupin has been under the regulatory lens recently, with the company’s Tarapur plant receiving a warning letter last month for an inspection conducted between March and April this year.
The unit received an Official Action Initiated (OAI) status in January 2020, followed by four observations on reinspection in April this year.
A warning letter was also issued to the company’s Goa plant in 2017; it was later lifted in December of the same year.
Its unit in Somerset, New Jersey received an Establishment Inspection Report (EIR) in July this year with a Voluntary Action Initiated (VAI) status.
Among other pending regulatory issues for the company, its Pithampur Unit 2 was issued a warning letter in November 2017, followed by six observations during the reinspection in January 2019.
Lupin’s Mandideep Unit 1 formulation + API unit is also under a warning letter from the USFDA since September 2019.
The management said that it remains committed to resolving the issues with the regulator expeditiously.
Lupin had reported disappointing results for the June quarter, dragged down by a 30 percent sequential decline in its US business, which saw sales fall to a multi-year low.
The company’s margins also fell to single digits during the quarter.
However, the street is estimating a sharp recovery for Lupin’s US sales in the September quarter.
Operating margin is also likely to improve this quarter due to the potential recovery in the US business along with cost-cutting measures.
Lupin shares are down nearly 30% this year and are among the worst performers on the Nifty Pharma index.
USFDA issues form 483 with four observations to Alembic Pharma
USFDA issues 2 observations on Form 483 to Zydus Lifesciences
USFDA issues Form 483 to Indoco with zero observation
USFDA issues Form 483 with 11 observation to Biocon
USFDA issues Form 483 with 2 observation to Alembic
USFDA issues Form 483 with one observation to Aurobindo Pharma subsidiary’s plant
Govt notifies rules to exempt certain medical devices under Class A
PCI to implement Pharmacy Practice Regulations, 2015
Drug alert: 59 out of 1456 samples declared as NSQ in September 2022
Govt notifies rules to ease New Drugs and Clinical Trials norms
USFDA issues form 483 with four observations to Alembic Pharma
Govt brings these eight substances under NDPS Act
CDSCO Panel gives nod to study Anti Allergic Combination Drug
DCGI notifies classification of 48 Medical Devices related to Oncology under MDR 2017
Procedure to obtain registration for Blood Storage Centre
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
